649 related articles for article (PubMed ID: 29281999)
21. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
22. The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis.
Wu Y; Zhang N; Yang Q
BMC Cancer; 2017 Dec; 17(1):839. PubMed ID: 29228910
[TBL] [Abstract][Full Text] [Related]
23. The impact of molecular status on survival outcomes for invasive micropapillary carcinoma of the breast.
Lewis GD; Xing Y; Haque W; Patel T; Schwartz MR; Chen AC; Farach A; Hatch SS; Butler EB; Chang JC; Teh BS
Breast J; 2019 Nov; 25(6):1171-1176. PubMed ID: 31321854
[TBL] [Abstract][Full Text] [Related]
24. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Mavroudis D; Saloustros E; Malamos N; Kakolyris S; Boukovinas I; Papakotoulas P; Kentepozidis N; Ziras N; Georgoulias V;
Ann Oncol; 2015 Jul; 26(7):1333-40. PubMed ID: 25935793
[TBL] [Abstract][Full Text] [Related]
25. A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.
Shigematsu H; Nakamura Y; Tanaka K; Shiotani S; Koga C; Kawaguchi H; Nishimura S; Taguchi K; Nishiyama K; Ohno S
Int J Clin Oncol; 2010 Dec; 15(6):615-20. PubMed ID: 20473628
[TBL] [Abstract][Full Text] [Related]
26. Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast.
Chen AC; Paulino AC; Schwartz MR; Rodriguez AA; Bass BL; Chang JC; Teh BS
Br J Cancer; 2014 Jul; 111(3):619-22. PubMed ID: 24921921
[TBL] [Abstract][Full Text] [Related]
27. Breast carcinoma with micropapillary features: clinicopathologic study and long-term follow-up of 100 cases.
Chen L; Fan Y; Lang RG; Guo XJ; Sun YL; Cui LF; Liu FF; Wei J; Zhang XM; Fu L
Int J Surg Pathol; 2008 Apr; 16(2):155-63. PubMed ID: 18417672
[TBL] [Abstract][Full Text] [Related]
28. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Llombart-Cussac A; Cortés J; Paré L; Galván P; Bermejo B; Martínez N; Vidal M; Pernas S; López R; Muñoz M; Nuciforo P; Morales S; Oliveira M; de la Peña L; Peláez A; Prat A
Lancet Oncol; 2017 Apr; 18(4):545-554. PubMed ID: 28238593
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of TNF-alpha and TNFRII in invasive micropapillary carcinoma of the breast: clinicopathological correlations.
Cui LF; Guo XJ; Wei J; Liu FF; Fan Y; Lang RG; Gu F; Zhang XM; Fu L
Histopathology; 2008 Oct; 53(4):381-8. PubMed ID: 18764880
[TBL] [Abstract][Full Text] [Related]
30. High snail expression predicts a poor prognosis in breast invasive ductal carcinoma patients with HER2/EGFR-positive subtypes.
Chang HY; Tseng YK; Chen YC; Shu CW; Lin MI; Liou HH; Fu TY; Lin YC; Ger LP; Yeh MH; Liu PF
Surg Oncol; 2018 Jun; 27(2):314-320. PubMed ID: 29937187
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
Jang N; Kwon HJ; Park MH; Kang SH; Bae YK
Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719
[TBL] [Abstract][Full Text] [Related]
32. Loss of ARID1A expression is associated with poor prognosis in invasive micropapillary carcinomas of the breast: A clinicopathologic and immunohistochemical study with long-term survival analysis.
Onder S; Fayda M; Karanlık H; Bayram A; Şen F; Cabioglu N; Tuzlalı S; İlhan R; Yavuz E
Breast J; 2017 Nov; 23(6):638-646. PubMed ID: 28543794
[TBL] [Abstract][Full Text] [Related]
33. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.
Vaz-Luis I; Seah D; Olson EM; Wagle N; Metzger-Filho O; Sohl J; Litsas G; Burstein HJ; Krop IE; Winer EP; Lin NU
Clin Breast Cancer; 2013 Aug; 13(4):254-63. PubMed ID: 23829891
[TBL] [Abstract][Full Text] [Related]
35. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
[TBL] [Abstract][Full Text] [Related]
36. Amplification and overexpression of PSCA at 8q24 in invasive micropapillary carcinoma of breast.
Meng F; Liu B; Xie G; Song Y; Zheng X; Qian X; Li S; Jia H; Zhang X; Zhang L; Yang YL; Fu L
Breast Cancer Res Treat; 2017 Nov; 166(2):383-392. PubMed ID: 28755148
[TBL] [Abstract][Full Text] [Related]
37. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
38. [Significance of interleukin-1beta expression and microvascular density in invasive micropapillary carcinoma of breast].
Cui LF; Guo XJ; Wei J; Liu FF; Gu F; Fan Y; Lang RG; Fu L
Zhonghua Bing Li Xue Za Zhi; 2008 Sep; 37(9):599-603. PubMed ID: 19094583
[TBL] [Abstract][Full Text] [Related]
39. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
40. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.
Pivot X; Pegram M; Cortes J; Lüftner D; Lyman GH; Curigliano G; Bondarenko I; Yoon YC; Kim Y; Kim C
Eur J Cancer; 2019 Oct; 120():1-9. PubMed ID: 31445454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
